Skip to main content

Table 4 Type of AML, cytogenetic risk category, and BMBC in patients in the 12 studies evaluated in the meta-analysis

From: Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis

Study name (Other identifier)

Sample size

Tx

Type of AML

Cytogenetic risk category

BMBC, median (range)

De novo,

n (%)

Secondary,

n (%)

Therapy-related,

n (%)

Poor,

n (%)

Intermediate,

n (%)

No mitosis,

n (%)

AZA-AML-001 [20]

241

AZA

66.6 (24.7%)a

CALGB 11,002 [19]

82

DEC

Short 2019 [21]

28

DEC 5-day

13 (46.4)

40 (29–68)b

43

DEC 10-day

18 (41.9)

46 (25–64)b

VIALE-A [6]

145

AZA

110 (75.9)

26 (17.9)

9 (6.2)

56 (38.6)

89 (61.4)

286

VEN + AZA

214 (74.8)

46 (16.1)

26 (9.1)

104 (36.4)

182 (63.6)

DiNardo 2018 [22]

84

VEN + AZA

33 (39.3)

50 (59.5)

1 (1.2)

31

VEN + DEC

15 (48.4)

16 (51.6)

DiNardo 2020 [23]

37

VEN + DEC

26 (–)a

Kadia 2015 [24]

293

HDAC/HMA

Short 2020 [25]

202

IDAC- or HDAC-based/HMA ± VEN

30 (14.9)

52 (25.7)

32 (3–97)

Lindsley 2019 [26]

156

7 + 3 cytarabine + daunorubicin

Prochazka 2019 [13]

98

IC

82 (83.7)

4 (4.1)

12 (12.2)

2 (2.0)

11 (11.2)

71 (72.4)

60 (14–100)

Chiche 2021 [27]

103

CPX-351 (daunorubicin + cytarabine)

27 (26.2)

Desoutter 2014 [28]

96

AZA

53 (55.2)

14 (14.6)

61 (63.5)

21 (21.9)

14 (14.6)

15 (0–95)

  1. AML acute myeloid leukemia, AZA azacitidine, BMBC bone marrow blast count, DEC decitabine, HDAC high-dose cytarabine, HMA hypomethylating agent, IC intensive chemotherapy, IDAC intermediate-dose cytarabine, Tx treatment, VEN venetoclax
  2. aMean (± SD)
  3. bMedian (± IQR)